New drug teduglutide monitored in 250 patients with short bowel syndrome
NCT ID NCT05023382
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 250 people in Japan with short bowel syndrome who are receiving teduglutide (Revestive) injections. Researchers will monitor side effects and how well the drug controls symptoms over 36 months. The goal is to see if teduglutide can safely reduce the need for intravenous nutrition support.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Teduglutide (Revestive) injection
What this could lead to
If successful, this could confirm that teduglutide safely reduces the need for intravenous nutrition in people with short bowel syndrome.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Side effects are possible, and benefits may vary among patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHORT BOWEL SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Takeda Selected Site
Tokyo, Japan